MRNA - Spark Newswire

4 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

Today, 7:13 AM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ABT

2 minute read

European Medicines Agency Committee For Medicinal Products For Human Use Adopts Opinion Recommending Authorization Of Moderna’s Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union

By Benzinga Newsdesk

Today, 7:13 AM

Positive recommendation follows the recent approval of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), a bivalent booster vaccine targeting the Omicron BA.1 subvariant, in September CAMBRIDGE, MA / ACCESSWIRE /

MRNA

1 minute read

European Medicines Agency Says Committee for Medicinal Products for Human Use Concluded That Benefits Of Comirnaty And Spikevax In Children Aged From 6 Months To 4 And 5 Years, Respectively, Outweigh Risks

By Benzinga Newsdesk

Today, 7:13 AM

- Reuters

BNTX

1 minute read

EMA Says In Children From 6 Months To 4 Years Of Age, Comirnaty Can Be Given As Primary Vaccination Consisting Of Three Doses; In Children From 6 Months To 5 Years Of Age, Spikevax Can Be Given As Primary Vaccination Consisting Of Two Doses

By Benzinga Newsdesk

Today, 7:13 AM

- Reuters

BNTX

7 minute read

News

European Medicines Agency Says Committee for Medicinal Products for Human Use Has Recommended Extending The Use Of Comirnaty And Spikevax Targeting The Original Strain Of Sars-Cov-2

By Benzinga Newsdesk

Today, 7:13 AM

Pfizer Inc.

BNTX

2 minute read

Moderna Announces 90-Day Analysis Showing Co.’s Omicron BA.1-Targeting Bivalent Vaccine Showed Superior Antibody Response Compared To Spikevax Prototype Booster

By Benzinga Newsdesk

Today, 7:13 AM

Data indicate durable immune response from bivalent booster after three months of follow-up mRNA-1273.214 also demonstrated potent response to Omicron BA.2.75 CAMBRIDGE, MA / ACCESSWIRE / October 19, 2022

MRNA

1 minute read

What’s Going On With Moderna Stock Today

By Henry Khederian

Today, 7:13 AM

Moderna Inc (NASDAQ: MRNA) shares are trading lower by 4.11% to $133.52 going into the close of Tuesday's session after Morgan Stanley maintained an Equal-Weight rating on the stock and cut its price target from $197 to $175. What Else?

MRNA